Prolatan is a prescription medication indicated for the reduction of elevated intraocular pressure (IOP). This use applies to patients who have been diagnosed with open-angle glaucoma or ocular hypertension. Managing elevated IOP is a key strategy to support the health of the optic nerve and potentially assist in preventing progressive vision loss associated with these conditions. Prolatan is used as a component of a larger treatment plan designed by a healthcare professional.

It offers a therapeutic effect that helps to manage the pressure levels within the eye, providing support for overall visual function and stability. The common clinical goal is to maintain IOP within a target range.

Quick Fact: Relief for Elevated Eye Pressure

The use of this treatment is intended to favorably influence the course of the condition by addressing the pressure component.

The eligibility profile for Prolatan (Latanoprost) is defined by official regulatory agencies and is strictly based on a patient’s medical history, age, and physiological status.

Eligibility Status	Patient Group and Condition
Approved Use	Adults and the elderly diagnosed with open-angle glaucoma or ocular hypertension.
Absolute Contraindication	Known hypersensitivity to the active substance (Latanoprost) or any excipient, and patients with active herpetic keratitis.

Conditional and Restricted Use:

Prolatan is not recommended for use during pregnancy or breastfeeding. Age-related eligibility is limited, as the medicine is generally not established for children and adolescents under 18 and is not recommended for premature infants. Conditional use is required for patients with a history of recurrent herpetic keratitis, active intraocular inflammation (such as iritis or uveitis), or those at risk for macular edema (such as being aphakic or pseudophakic with a torn posterior lens capsule). These official restrictions define the specific population boundaries for the use of the medicine.

Interactions with other medicines and products

The regulatory interaction profile for Prolatan (Latanoprost ophthalmic solution) focuses primarily on constraints related to co-administered eye medicines and administration frequency, as definitive systemic metabolic drug interaction data are not available. The official documentation identifies specific interaction constraints within the local ophthalmic environment.

Pharmacodynamic Conflict and Restrictions

The concomitant ophthalmic administration of two or more prostaglandins, prostaglandin analogues, or derivatives is not recommended by regulatory authorities. This restriction is based on a documented pharmacodynamic conflict that can cause a paradoxical elevation in intraocular pressure (IOP), thereby counteracting the intended pressure-lowering effect.

Timing-Based and Physical-Chemical Incompatibilities

A mandatory time separation rule is required for proper administration. Any other topical ophthalmic drug product must be administered at least five (5) minutes apart from Prolatan to prevent potential washout and altered absorption. Furthermore, in vitro studies have demonstrated a physical-chemical incompatibility: precipitation occurs when the Latanoprost solution is mixed with eye drops that contain Thimerosal.

Frequency-Dependent Interaction

An official constraint exists regarding administration frequency. Using Latanoprost more than once daily is associated with a reduction in the expected IOP-lowering effect and may also result in paradoxical elevations in IOP. Regulatory documentation does not report interactions with food, alcohol, or herbal products.

Selective Activation of Prostanoid FP Receptors

Prolatan's mechanism begins at the molecular level with the active metabolite, Latanoprost acid, which acts as a selective agonist at the Prostanoid FP Receptor located primarily on the cells of the ciliary muscle. This targeted receptor binding initiates the entire biological cascade, as this specific receptor is a key modulator of structural changes in the eye's outflow tissues.

---

️ Tissue Remodeling via Extracellular Matrix Modulation

Following receptor activation, the signal transduction pathway increases the activity of local enzymes, specifically Matrix Metalloproteinases (MMPs), which function to remodel the Extracellular Matrix (ECM) between the ciliary muscle bundles. This process physically widens the spaces and reduces the tissue's density, resulting in a highly permeable environment for fluid clearance.

---

Enhanced Uveoscleral Outflow and Pressure Reduction

This molecular and structural remodeling of the ciliary muscle and surrounding scleral tissue directly enhances the passage of aqueous humor through the uveoscleral outflow pathway, which is the secondary and pressure-insensitive drainage route. The result of this enhanced fluid clearance is a sustained reduction in Intraocular Pressure (IOP). The mechanism is dependent on this remodeling and therefore does not produce an immediate maximum effect.

Administration Overview

Prolatan is an ophthalmic solution intended for topical application to the eyes. Proper administration technique is important to ensure the solution is delivered effectively to the ocular surface.

Application Procedure

To apply the solution, the following general steps are typically followed:

• Preparation: Wash hands thoroughly before handling the bottle to maintain sterility. Remove the cap and place it on a clean surface.
• Positioning: Tilt the head back slightly or lie down. Using a finger, gently pull the lower eyelid downward to create a small pocket.
• Instillation: Hold the dropper bottle above the eye without allowing the tip to touch the eye, eyelashes, or any other surface. Squeeze the bottle gently to release the required amount of solution into the conjunctival sac.
• Closing the Eye: Close the eye gently for several minutes. Do not rub the eye or blink excessively immediately after application.
• Nasolacrimal Occlusion: Applying gentle pressure to the inner corner of the eye (near the nose) for about one minute can help minimize systemic absorption of the solution.

Use with Contact Lenses

Prolatan contains a preservative that may be absorbed by soft contact lenses. It is generally recommended to remove contact lenses prior to the application of the drops. Lenses may typically be reinserted after a short period following the instillation of the solution.

Use with Other Ophthalmic Medications

If more than one topical ophthalmic medication is being used, the different solutions should be administered at different times. A specific interval between applications is necessary to prevent the second drop from washing out the first and to ensure both medications are properly absorbed.

Research Evidence / Overview of Studies for Prolatan (Latanoprost)

---

Research Evidence for Open-Angle Glaucoma

The active substance Latanoprost was studied for use in patients diagnosed with Primary Open-Angle Glaucoma. Research exploring this condition used Randomized Controlled Trials (RCTs). These RCTs often were evaluated in adult patients with high eye pressure and involved comparisons either against an inactive substance (a vehicle) or against other established eye pressure medications. The main focus of these studies was to monitor the change (often documented as reduction) in Intraocular Pressure (IOP) from the baseline measurement. This IOP measurement is commonly considered a surrogate endpoint.

Multiple studies reported measurements related to a reduction in IOP over the study period compared to baseline values. These findings help contextualize short-term pressure measurements, and the evidence contributes to the broader evidence landscape.

Despite the available body of research focusing on IOP reduction, long-term effects are not fully established regarding the definitive clinical outcomes. Follow-up durations were limited in many of the key trials. Findings describe group patterns; research does not provide individual predictions regarding response.

---

Research Evidence for Ocular Hypertension

Latanoprost was studied for use in patients with Ocular Hypertension, a condition marked by elevated eye pressure. Short-term Randomized Controlled Trials were observed in these populations. The research examined the initial response of IOP when the medicine was applied.

Short-term studies reported measurements related to a reduction in mean IOP in the population studied over the course of the trial. These findings describe group patterns, offering context on how pressure control was studied for this population.

The research primarily focuses on the IOP-lowering effect being a surrogate endpoint. The evidence is limited in providing long-term data on the definitive outcome of preventing the conversion from ocular hypertension to confirmed glaucoma. Furthermore, follow-up durations were limited in these initial trials; therefore, the long-term maintenance of pressure control is not fully established.

---

Areas of Research Uncertainty and Study Gaps

Certain areas remain uncertain or are subjects of ongoing research. The primary limitation is the fundamental reliance on IOP reduction as a surrogate endpoint in most clinical trials. This means the research highlights what is known about pressure changes but does not determine, with the highest certainty, the medicine’s definitive impact on preserving the optic nerve over a patient’s lifetime.

Also, data for certain groups remain insufficient, especially for specific secondary forms of glaucoma or populations with complex medical histories, as sample sizes were modest in these subgroups. The evidence quality varies across studies focusing on different populations or specific clinical settings.

Common questions about Prolatan (FAQ)

---

Q: Is Prolatan a monotherapy or can it be used with other glaucoma medicines?

According to official regulatory documents, Prolatan (latanoprost) can be used together with other types of topical eye drops to lower intraocular pressure. However, the use of two or more prostaglandin-based eye drops together is not recommended, as this combination may interfere with the intended pressure-lowering effect.

Q: Where exactly does Prolatan work inside the eye?

Prolatan's active ingredient targets specific receptors located on the ciliary muscle inside the eye. The mechanism involves stimulating these receptors, which is associated with increasing the drainage of fluid, called aqueous humor, primarily through a pathway known as the uveoscleral outflow.

Q: Can I take these drops if I am pregnant?

Official product information states that Prolatan is not recommended for use during pregnancy, as safety has not been established. Consultation with a healthcare provider is necessary to weigh potential benefits against risks for individuals who are pregnant or planning to become pregnant.

Q: How long does it take for Prolatan to start lowering my eye pressure?

Official pharmacological data indicates that the pressure-lowering effect of Prolatan typically begins approximately three to four hours after the eye drop is administered. The maximum reduction in eye pressure is generally reached within 8 to 12 hours after the dose.

Q: What is the difference between Prolatan and other eye pressure drops?

Prolatan is categorized as a Prostaglandin Analog, which means its primary function is to lower eye pressure by increasing the outflow (drainage) of fluid from the eye. Other classes of eye drops for glaucoma may operate through different mechanisms, such as reducing the amount of fluid the eye produces.

Storage and Disposal Requirements

The official storage and disposal guidelines for Prolatan (latanoprost ophthalmic solution) are mandated by regulatory agencies to maintain product stability and safety.

Storage Conditions

Product Status	Required Temperature	Additional Protection
Unopened	Refrigerated: 2 C to 8 C (36 F to 46 F)	Protect from light; Do not freeze
Opened (In-Use)	Room Temperature: Up to 25 C (77 F)	Discard any remaining solution after six weeks

The medication must be kept in its original container and stored out of the reach of children. The container tip must not touch any surface, including the eye, to prevent contamination.

Disposal

Unused or expired Prolatan must not be thrown into household waste or flushed down the drain (wastewater). Disposal must adhere to local regulations; official drug take-back programs are the preferred method for discarding the unused product.